Cigna director receives 782-share stock grant

ZARCONE DONNA F reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

ZARCONE DONNA F reported acquisition or exercise transactions in this Form 4 filing.

Cigna Group director Donna F. Zarcone received an award of 782 shares of common stock on April 22, 2026. The grant was compensation-related, with no purchase price per share reported. Following this award, her directly owned holdings increased to 27,517 shares of Cigna common stock.

Her overall economic interest also includes cash-settled hypothetical shares tied to Cigna’s stock value, which are not shown in the share table because they are paid in cash rather than stock upon separation from service.

Insider Trade Summary

Grant/Award: 782 shares

Grant/Award 1 txn

Insider ZARCONE DONNA F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $.01 Par Value	782	$0.00	$0.00

Holdings After Transaction: Common Stock, $.01 Par Value — 27,517 shares (Direct)

Footnotes (1)

1. F1. The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.

Key Figures

Shares granted: 782 shares Price per share: $0.00 per share Shares owned after grant: 27,517 shares +1 more

4 metrics

Shares granted 782 shares Equity award on April 22, 2026

Price per share <money>$0.00</money> per share Reported grant price

Shares owned after grant 27,517 shares Direct holdings following transaction

Transaction code A (Grant, award, or other acquisition) Non-derivative common stock

Key Terms

hypothetical shares, Section 16 filings, proxy statement, Grant, award, or other acquisition

4 terms

hypothetical shares financial

"The reporting person's economic interest ... also includes hypothetical shares of common stock"

Section 16 filings regulatory

"please see the reporting person's Section 16 filings for The Cigna Group"

proxy statement regulatory

"The Cigna Group's proxy statement filed with the SEC on March 13, 2026"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZARCONE DONNA F

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CONNECTICUT 06002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	04/22/2026		A		782	A	$0	27,517(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	Tyler Gratton, attorney-in-fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)